It looks like there won’t be any Yelp reviews, color-coded drugs, or seasteading in the Food and Drug Administration’s future. Instead, President Donald Trump is going with the establishment candidate — and the biotech industry couldn’t be more relieved.
Dr. Scott Gottlieb, a former deputy commissioner at FDA who also has a Wall Street pedigree, is Trump’s nominee to lead the agency, ending months of speculation and consternation among biotech insiders.
About the Author Reprints
May I observe that until Scott is formally designated as the nominee and the Senate approves him, it is too early to celebrate. While this potential choice counts as a pleasant surprise, the President always seems to have ‘another surprise’ in the wings. Senate confirmation first then pop the corks, assuming, of course, that now the nomination is set.